Robert Iannone | executive |
Bruce Cozadd | executive |
Jessica Fye | analyst |
Jason Gerberry | analyst |
Kim Sablich | executive |
Ami Fadia | analyst |
Marc Goodman | analyst |
Balaji Prasad | analyst |
David Amsellem | analyst |
Gregory Renza | analyst |
Lee Hung | analyst |
Mohit Bansal | analyst |
[Audio Gap] large orders of fast food french fries or 5 large bags of potato chips every night before bed, or that it would take 12 years of treatment with Xywav to equal the sodium intake of 1 year of high sodium oxybate treatment. Regardless of the parallels we draw, the bottom line is clear. The sodium reduction offered by Xywav had significant potential health benefits, including lower blood pressure and improved cardiovascular health. We recently presented data at the World Sleep Meeting that built on our body of research demonstrating the clear relationship between sleep disorders and increased cardiovascular risk, as well as the meaningful improvements possible with treatment plans that consider a patient's holistic health, such as reducing sodium intake. And earlier this year, we shared data at the American Academe Neurology meeting that should narcolepsy patients treated with high sodium oxybate had a higher risk of new onset hypertension diagnosis or anti-hypertensive medication initiation within 180 days of starting therapy when compared to a match control group of narcolepsy patients not being treated with high sodium oxybate.